After abuse-deterrent opioid formulations reached a dead-end, the US Food and Drug Administration again is seeing growth in applications for new products that address the opioid crisis. In addition to two applications for OTC naloxone nasal sprays for overdose reversal, the agency is reviewing proposals for a potential Rx competitor and two prescription rescue products that aspire to address high-potency synthetic opioid overdose.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?